STOCK TITAN

InMed Pharmaceuticals officer holds 62,273 options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reports that Brett R. Hagen, its Senior Vice President, Finance and Chief Accounting Officer, directly holds options to purchase 62,273 shares of common stock at an exercise price of $10.37 per share, expiring September 24, 2036. The options were received in the merger effective November 6, 2026, in exchange for options in Pre-Merger Mentari. They vest as to 25% on August 3, 2027, with equal monthly installments thereafter through August 3, 2030, subject to his continued service on each vesting date.

Insider Hagen Brett R
Role See Remarks
Type Security Shares Price Value
Holding Stock Option (Right to Buy) F1, F2 -- -- --
Holdings: Stock Option (Right to Buy) — 62,273 options (Direct)
Footnotes (2)
  1. F1. Effective as of November 6, 2026, (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
  2. F2. Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Mentari held by the Reporting Person prior to the Merger. This option will vest as to 25% on August 3, 2027 and in equal monthly installments thereafter through August 3, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Underlying common shares 62,273 shares Shares purchasable under Brett R. Hagen’s directly held options
Exercise price $10.37 per share Price to exercise the options
Expiration date September 24, 2036 Expiration of the reported options
Initial vesting 25% Vests August 3, 2027, subject to continued service
vesting technical
"will vest as to 25% on August 3, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Stock Option (Right to Buy) technical
"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options does InMed Pharmaceuticals (INM) officer Brett R. Hagen hold?

Brett R. Hagen directly holds options to purchase 62,273 shares of common stock.

What is the exercise price of Brett R. Hagen’s InMed (INM) options?

The options have an exercise price of $10.37 per share and expire September 24, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Hagen Brett R

(Last)(First)(Middle)
C/O MENTARI THERAPEUTICS, INC.
221 CRESCENT ST., BUILDING 23, SUITE 105

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2026
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (1)(2)09/24/2036Common Stock62,273$10.37D
Explanation of Responses:
1. Effective as of November 6, 2026, (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
2. Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Mentari held by the Reporting Person prior to the Merger. This option will vest as to 25% on August 3, 2027 and in equal monthly installments thereafter through August 3, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks:
Senior Vice President, Finance and Chief Accounting Officer Exhibit 24 - Power of Attorney
/s/ Jerad G. Seurer, as attorney-in-fact for Brett Hagen11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading